Research to market/public good: Economic perspectives by Hardy, Ralph W.F.
This presentation provides an overview of the NaBC-8 theme, Economic Development 
Through New Products, Partnerships and Workforce Development, from an economic per-
spective. With special reference to agricultural (bio)technology, specifically it outlines 
methods used for science/technology transfer to markets and public good, provides public 
and private sector examples of venture capital for early commercialization of agricultural 
science and technology, and describes issues and recommendations for effective technol-
ogy transfer to market including public good.
The views expressed in this presentation are mine based on experience in academia, 
large and start-up industry, and government including as a board member of a government 
venture-capital corporation [alternative agricultural research and Commercialization 
(aarC) Corporation] and as an advisory board member of a private venture-capital cor-
poration (Foragen technologies, Inc.). as president of NaBC and a last-minute substitute 
speaker for roger Wyse of Burrill & Company, a life sciences merchant bank, I emphasize 
that the views expressed here are not necessarily those of NaBC.
Economic Methods Used for technology transfer
Licensing
Much of the research by not-for-profit institutions, e.g. universities, government labo-
ratories, research institutes, is to generate knowledge, but such research also results in 
innovation with potential for commercial products and processes and public good. The 
majority of not-for-profit research is in this area, with most funding from the public sec-
tor. Based on the source of the funding and the mission of the not-for-profit institutions, 
it is their obligation to provide benefits to the public. In the past, plant breeding utilized 
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public varieties as the transfer vehicle, but such transfer nowadays usually is done by 
licensing. In 004, the top ten US universities (based on $$ of sponsored research) had 
$0 billion of sponsored research and gross licensing revenues of less than $300 million, 
or less than 3% of the sponsored research, ranging from 0.4% to 7% (Laurence, 006). 
Licensing revenue makes a very small contribution to not-for-profit research, is highly 
variable and is not very predictable. The historic examples are the University of Wisconsin 
vitamin-D irradiation of milk and the rodent poison and human blood thinner warfarin, 
and more recently the Stanford/University of California fundamental process for making 
transgenics. Most not-for-profit institutions have established technology-transfer offices. 
In Issues and Recommendations below, I will recommend that maximization of public good 
should be the objective of technology transfer, not maximization of revenue. This view 
will be amplified by Mark Crowell in his presentation on Knowledge Transfer and Economic 
Development: The Role of the Engaged University in the Twenty-First Century.
Research Contracts
For-profit corporations provide contract support for not-for-profit research with the 
objective of generation of technology/know-how for improvement of existing products 
or processes or development of new products and processes. research contracts may rep-
resent 5% to 0% of research support for more-applied not-for-profit research, such as 
agriculture and biotechnology. In most cases, the funder will obtain exclusive commercial 
rights to the technology, including patents for a license fee that is probably predetermined. 
It is preferable that the not-for-profit entity, not the funding industry, be the owner of 
the intellectual property, with licensing of rights to the industry. research rights should 
be maintained by the not-for-profit. The government uses Cooperative research and 
Development agreements (CraDas) and these will be discussed by richard Brenner 
in his presentation, Technology Transfer in ARS: Implications of Federal/Private Sector and 
Federal/University Partnerships to Commercialization Strategies.
Maximization of public good should be the objective of 
technology transfer, not maximization of revenue.
It is preferable that the not-for-profit entity, not the funding 
industry, be the owner of the intellectual property, with licensing 
of rights to the industry.
44 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
Various Government Grants to Facilitate Early Development and 
Commercialization
These include Small Business Innovation research (SBIr) grants to facilitate small-
company product and process development, such as feasibility studies and business-plan 
development. William Goldner will describe this program (The USDA Small Business 
Innovative Research Program: Vision, Challenge, and Opportunity). The Defence advanced 
research Projects agency (DarPa) has a similar grants program. These programs are 
important for cash-strapped new companies since they do not require repayment, and 
Michael adang (From the Bench to a Product: Academics and Entrepreneurship) will provide 
a real example. The Department of Energy (DOE) has used major grants to drive biobased 
industrial products with major industry often the lead organization with subcontracts to 
other industries and not-for-profits; a recent example is the multifold reduction in cost 
of cellulase enzymes for use with cellulosics for ethanol production.
Technology Parks
technology parks have been shown to be useful in bridging the so-called “valley of death,” 
the gap between laboratory research and resultant potential technology and conversion 
to a commercial endeavor. Such parks enable direct interaction between the scientific 
innovator and the company seeking to develop and commercialize the product or pro-
cess. Presentations by allen Dines (From Equines to Economic Development: The Story of 
University Research Park) will describe the highly successful three-pronged approach in 
Wisconsin with over 80 years of highly successful experience and by ashley O’Sullivan 
(From Tools to Products and Processes: The Evolution of Saskatchewan’s Ag Biotech Cluster) 
who will describe what is probably the most successful agriculturally focussed technol-
ogy park with about 0 years experience. Our visit to the Cornell agricultural and Food 
technology Park (CaFtP) in Geneva, NY, will provide an opportunity to explore issues 
facing a “just born” technology park.
International Examples
Other presentations at this meeting will provide examples from other countries of the 
transfer of research to market and the public. Zhangliang Chen (Innovation: The Chinese 
Experience) will describe the connected relationship between the university and the es-
tablishment and operation of major businesses, with substantial economic benefit to the 
university; such a relationship probably would not be acceptable in the United States. Wim 
Jongen (Food for Innovation) will describe the Wageningen Business Generator, which 
has similarities to Canadian and US research parks. Other examples include India, Brazil 
and Germany. This broad experience-base, and their respective strengths and weaknesses 
should guide future activities in this emerging area of technology transfer. a reality check 
is provided by richard Broglie (Translating Discovery Research into Commercial Products), 
presenting the perspective of a major agri-food-chemical company.
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Various Forms of Investment in New Companies
Equity investment is more useful for new companies than loans; new companies are 
almost always strapped for cash and, therefore, interest payments consume money that 
is needed to invest in the business. I have had several years’ personal experience with a 
government-funded venture-capital corporation and with a privately funded venture-
capital corporation. Both were investors in early-stage commercialization.
The aarC Corporation was authorized by the 990 Farm Bill as a wholly owned 
government corporation within USDa. Its mission was to commercialize industrial uses 
of ag and forestry materials to create, in the long term, new markets and reduce subsidies 
for agriculture. aarC had many strengths, including a mainly non-bureaucrat board with 
initially over 50% having been presidents or vice-presidents of for-profit corporations. 
It was operated as a business, making investments in the most promising companies, 
with little emphasis on geographic location and with ability to make equity investments, 
which was unique to government where grants and low-interest loans were the norm, 
requiring matches of at least : of non-aarC to aarC investments, and in-depth due 
diligence with external expert review of proposals and on-site reviews by staff and at least 
one board member, prior to investment, with subsequent on-site annual or more-frequent 
monitoring. The weaknesses were the inexperience of government with venture-capital and 
the venture-capital approach where projected return is directly variant with risk, impact 
of shifting political “winds” on funding, ability only to invest if private funds were not 
available (in other words, the source of last resort) and, finally, the inability to move the 
“aarC activity” to a non-government-funded corporation with expanded resources for 
continuing and expanded equity investments in biobased products and processes. Equity 
funding for agriculture-related new companies is minimal; an exception may be occurring 
with the current exploding interest of Wall Street in cornstarch-ethanol investment where 
the possibility of too much/too fast is a real concern. There is a major continuing need 
for government to play a role with early venture capital, but it would need to avoid the 
above weaknesses. Up-front endowment-type government funding may work, as with the 
very successful Canadian Foundation for Innovation in the late 990s.
Examples of products/processes funded by aarC [e.g. aarC Corporation (997)] 
included milkweed fiber for hypoallergenic comforters and pillows, D-ribose for cardio-
vascular function, biodegradable plant oils for engine lubrication, capsaicins from hot 
peppers to keep mammals out of avian food, e.g. squirrel-free birdseed, and gasification 
of biomass and its high-yield biological conversion to ethanol.
Foragen technologies, Inc., is a Canada-based venture-capital company founded in the 
late 990s. Funding came from the private sector. It funded very early commercialization 
as mainly not-for-profit innovations were evaluated and developed as new businesses. a 
number of promising investments were made. However, a second round of investment in 
Foragen technologies by the private sector did not occur, probably based on the percep-
tion that agriculture is not an attractive area for venture capital. This is in contrast to the 
abundant venture capital for human-health-related innovations.
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Issues and recommendations
Several issues and recommendations will be noted, with the hope of stimulating discussion 
and improving efficacy of research to market/public good transfers.
Maximize Public Good from Public-Sector Research
Licensing income is small. technology transfer should maximize public good not maxi-
mize licensing income1. Evaluations by and of technology-transfer offices should use the 
public-good metric, not the income metric.
Intellectual Property
Seeking protection of IP should be based on a realistic assessment of potential. Business-
experienced alumni can be helpful in providing guidance on decision-making regarding 
filing of patents. When it is decided not to file a patent, the right to file could be assigned 
to the inventors. The most promising patents should be filed broadly and patent estates 
built around them. Failure to find business interest in a patent within a reasonable time 
should lead to timely abandonment so as to avoid continuing maintenance costs. although 
universities file and are awarded large numbers of patents (rovner, 006), only a few 
result in significant products and/or processes
Venture Capital
Venture capital for agricultural innovations, other than human-health uses—is inadequate. 
a method is needed for significant government funding of this area without the variability 
of political impact. Up-front endowment funding may be such a method.
1robert E. armstrong, senior research fellow at the National Defence University, suggests that the apache 
“open source” community in the computer-software industry, as described by tom Friedman in The World 
is Flat (New York: Farrar, Straus and Giroux, 005), illustrates maximizing the public good while enabling 
economic return to industry. The apache “open source” community is a collaboration of computer scientists 
self-organized to develop programming to run Web services. In the apache collaborative community you could 
use community technology, but were required to make any improvements available to the community. In 
addition, industry could build a patented commercial product utilizing the “apache code,” but were required 
to include a copyright citation in their patent. Substantial revenue has been generated by IBM utilizing this 
approach in the Web-server business, while the base technology is broadly available. Plant breeding public 
research with seed-company development of commercial products is an earlier example. The recent collaboration 
of several not-for-profit research institutions to retain research uses and applications for developing-country 
uses of biotechnology patents is another example.
Path to Market
My experience is that the path to market is the single most decisive factor for success 
of a new company, more so than any other factor, such as entrepreneurial leadership, 
funding or technology.
The path to market is the single most decisive factor for success of 
a new company.
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Deal Yield
a large number of deals need to be assessed to find the few that are worthy of investment. 
The yield is in the range of one out of every twenty-five to fifty considered. “Back-of-the-
envelope” calculations eliminate many deals.
Business CEOs
Scientist innovators usually are not successful as business CEOs. a rule of one venture-
capital manager was “Shoot the inventor.” There are exceptions, but business CEOs need 
to focus, focus, focus on the business objectives, whereas scientists’ success usually results 
from broad curiosity.
Difficult Areas for New Businesses
Some examples where failure is common (based on my experience) are construction and 
building materials that require a huge scale of production, e.g. the 00 million ft straw-
based particleboard plant in Manitoba, most recently operated by Dow, was closed in 
early 006. another difficult area is new crops. Most are long-term efforts and need the 
staying power of the public sector. Canola, as described by Keith Downey (Rapeseed to 
Canola: Rags to Riches), is an example of relatively rapid development of a new crop, but 
there are many other oil (and other) crops for which development has been tortuous. 
another area with a low success rate is microbial pesticides. While plant-based biopesticide 
products have been quite successful, microbial pesticide-based companies have a history 
of failure. technology platforms are difficult in defining the business path to market.
There are other issues that I am sure will be discussed at the breakout sessions. I hope 
the above will help stimulate your discussions. Improving the transfer of research to the 
market/public good has major opportunities for improvement
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ralpH w.F. Hardy—a leader in science and management in 
the for-profit and not-for-profit sectors of the agricultural 
life sciences—has contributed significantly in the fields of 
biochemistry, physiology, and agronomy.
Dr. Hardy is president and co-founder of NaBC. Previ-
ously, he was president of Biotechnica International and 
president and CEO of the Boyce Thompson Institute for 
Plant research, Inc. He was with DuPont for  years, where he led the research-
driven diversification into pharmaceuticals, agricultural products, and biobased 
products. He is a leading spokesperson on the biobased economy and its potential 
for public good.
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